SG11202007739XA - Arginase inhibitors and methods of use thereof - Google Patents

Arginase inhibitors and methods of use thereof

Info

Publication number
SG11202007739XA
SG11202007739XA SG11202007739XA SG11202007739XA SG11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA
Authority
SG
Singapore
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
SG11202007739XA
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Jianyan Wang
Steve Cook
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202007739XA publication Critical patent/SG11202007739XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007739XA 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof SG11202007739XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202007739XA true SG11202007739XA (en) 2020-09-29

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007739XA SG11202007739XA (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Country Status (22)

Country Link
US (3) US11420984B2 (es)
EP (1) EP3752251A1 (es)
JP (2) JP7317841B2 (es)
KR (1) KR102657919B1 (es)
CN (3) CN111712302B (es)
AU (2) AU2019221896B2 (es)
BR (1) BR112020015973A2 (es)
CA (1) CA3091365A1 (es)
CL (1) CL2020002096A1 (es)
CR (1) CR20200418A (es)
DO (1) DOP2020000145A (es)
EC (1) ECSP20058183A (es)
IL (1) IL276711B2 (es)
JO (1) JOP20200197A1 (es)
MA (1) MA51837A (es)
MX (1) MX2020008570A (es)
NI (1) NI202000055A (es)
PE (1) PE20210176A1 (es)
SG (1) SG11202007739XA (es)
TW (1) TWI803574B (es)
UY (1) UY38096A (es)
WO (1) WO2019159120A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008570A (es) * 2018-02-17 2020-09-21 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso.
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CA3094939A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
KR102668252B1 (ko) 2018-08-22 2024-05-21 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
IL285108B1 (en) * 2019-02-08 2024-06-01 Astrazeneca Ab Arginase inhibitors and methods of using them
US20220409642A1 (en) 2019-11-04 2022-12-29 Astrazeneca Ab Combination therapy for treating cancer
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162535A (en) * 2010-04-22 2017-06-15 Mars Inc Inhibitors of arginase and their therapeutic applications
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
US8894970B2 (en) * 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
MX355758B (es) 2012-04-18 2018-04-27 Mars Inc Analogos constreñidos en el anillo como inhibidores de arginasa.
WO2016210106A1 (en) * 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
MA43131B1 (fr) 2015-10-30 2020-07-29 Calithera Biosciences Inc Compositions et procédés d'inhibition de l'activité de l'arginase
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2018089490A1 (en) * 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2019120296A1 (en) 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
MX2020008570A (es) * 2018-02-17 2020-09-21 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso.
US20210040127A1 (en) 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use

Also Published As

Publication number Publication date
US20230122859A1 (en) 2023-04-20
UY38096A (es) 2019-07-31
AU2019221896A1 (en) 2020-10-01
NI202000055A (es) 2021-06-22
US20230365599A1 (en) 2023-11-16
JP2023145557A (ja) 2023-10-11
US20210002305A1 (en) 2021-01-07
JP2021513964A (ja) 2021-06-03
TW201945004A (zh) 2019-12-01
CR20200418A (es) 2020-10-27
AU2019221896B2 (en) 2022-03-24
IL276711A (en) 2020-09-30
US11912727B2 (en) 2024-02-27
NZ767738A (en) 2023-12-22
CN117186134A (zh) 2023-12-08
CN117180290A (zh) 2023-12-08
KR102657919B1 (ko) 2024-04-15
TWI803574B (zh) 2023-06-01
EP3752251A1 (en) 2020-12-23
US11420984B2 (en) 2022-08-23
JOP20200197A1 (ar) 2020-08-16
CA3091365A1 (en) 2019-08-22
AU2022203938A1 (en) 2022-06-23
CL2020002096A1 (es) 2020-12-18
IL276711B1 (en) 2024-02-01
MA51837A (fr) 2021-06-16
BR112020015973A2 (pt) 2020-12-15
WO2019159120A1 (en) 2019-08-22
CN111712302A (zh) 2020-09-25
IL276711B2 (en) 2024-06-01
CN111712302B (zh) 2023-09-19
MX2020008570A (es) 2020-09-21
AU2022203938B2 (en) 2024-02-01
PE20210176A1 (es) 2021-01-29
ECSP20058183A (es) 2020-10-30
JP7317841B2 (ja) 2023-07-31
KR20200122341A (ko) 2020-10-27
DOP2020000145A (es) 2020-09-15

Similar Documents

Publication Publication Date Title
IL276711A (en) Arginase inhibitors and methods of using them
EP3700527A4 (en) PAPD5 INHIBITORS AND THEIR METHODS OF USE
IL287940A (en) fgfr inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL283592A (en) Apol1 inhibitors and methods of using them
IL284640A (en) PCSK9 inhibitors and methods of using them
IL287768A (en) kcnt1 inhibitors and methods of use
IL287973A (en) acss2 inhibitors and methods of their use
EP3765006A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL280924A (en) Arginase inhibitors and methods of using them
EP3810615A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL284661A (en) pcsk9 inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3897622A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
EP3846808A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL286485A (en) pi4-kinase inhibitors and methods of using them
IL286149A (en) Caspase inhibitors and methods of using them
EP3793552C0 (en) ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF
IL285108A (en) Arginase inhibitors and methods of using them
EP3787630A4 (en) FERROCHELATASE INHIBITORS AND METHODS OF USE